Key result
Factor V-Leiden mutation was detected in 56.9% of Lebanese DVT patients with suspected hypercoagulability, with higher rates in those younger than 50 years (68.6% vs 43.4%, P=0.041).
Why the study?
What is the incidence of Factor V-Leiden mutation among Lebanese patients with lower extremity venous thrombosis?
Population
283 consecutive Lebanese patients diagnosed with deep venous thrombosis by duplex scan, of which 65 patients…
Design
Cohort
Authors
Loading...
High Factor V-Leiden prevalence in Lebanese DVT, especially younger patients; leaves open whether ethnicity-tailored screening improves outcomes.
Observational (n=283)
What is the incidence of Factor V-Leiden mutation among Lebanese patients with lower extremity venous thrombosis?
The high prevalence of Factor V-Leiden mutation in Lebanese patients with DVT suggests that thrombophilia screening should be tailored to population-specific risk factors, particularly in younger patients.
Raghid Kreidy (2012) conducted an observational in Deep venous thrombosis (n=283). Factor V-Leiden mutation was evaluated on Detection of Factor V-Leiden mutation. Factor V-Leiden mutation was detected in 56.9% of Lebanese DVT patients with suspected hypercoagulability, with higher rates in those younger than 50 years (68.6% vs 43.4%, P=0.041).
Synapse has enriched one closely related paper. Consider it for comparative context: